Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Local levels of IL-1β and IF-α in patients with bullous keratopathy after UV-A corneal cross-linking

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Cross-Linking

Venue: Poster Village: Pod 2

First Author: : A.Khalimov RUSSIA

Co Author(s): :    M. Bikbov   N. Shevchuk                    

Abstract Details

Purpose:

To study concentration of IF-a and IL-1b in tear fluid of patients with bullous keratopathy after corneal UV-A cross-linking.

Setting:

Ufa Eye Research Institute, Ufa, Russia

Methods:

We examined 20 patients (12 men, 8 women) with bullous keratopathy, average age 36,3±3,2 years. The Control group consisted of 10 healthy individuals. UV-A CXL was performed according to standard procedures: Epi-off, 0.1% Riboflavin + 20% Dextran, UVA-irradiation 370 nm, 30 min, 3 mW/cm². Observations were made 3, 7 and 14 days after the UV-A CXL. The concentration (pg/ml) of IF-α and IL-1β in tear fluid was determined by ELISA 450 nm wavelength.

Results:

The preoperative level of IL-1β in tear fluid of patients with bullous keratopathy was elevated (2 to 4 times, p <0.05); IF-α level was within the normal range. On 3rd day after UV-A CXL with Epi-Off an increase in the preoperative levels of IL-1β and IF-α in the tear fluid was noted: IL-1β - from 8.29 to 18.61 pg / ml (p <0.05); IF-α - from 7.08 to 26.2 pg / ml (p <0.05). 7-14 days after UV-A CXL with Epi-Off the levels of IL-1β and IF-α decreased in the tear fluid from their maximum values.

Conclusions:

Bullous keratopathy is accompanied by a significant increase in the IL-1b level in the tear fluid at normal values of IF-α. The increase in levels of IL-1β and IF-α in the tear fluid of patients with bullous keratopathy on 3rd day after CXL may be associated with immunological response to de-epithelialization and UV-A irradiation of the cornea.

Financial Disclosure:

None

Back to previous